07:00 , May 23, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Cushing's disease Nuclear receptor subfamily 2 group C member 2 (NR2C2; TR4) Patient sample and mouse studies suggest inhibiting TR4 could help treat Cushing's disease....
08:00 , Nov 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Sickle cell disease Nuclear receptor subfamily 2 group C member 1 (NR2C1; TR2); NR2C2 (TR4) Studies in mice suggest upregulating TR2 and/or TR4 could help...
07:00 , Aug 6, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Nuclear receptor subfamily 2 group C member 2 (NR2C2; TR4); scavenger receptor class B member 3 (SCARB3; CD36) Studies in ex vivo murine...